Literature DB >> 24685448

Pulmonary artery invasion, high-dose radiation, and overall survival in patients with non-small cell lung cancer.

Cheng-Bo Han1, Wei-Li Wang2, Leslie Quint3, Jian-Xin Xue4, Martha Matuszak3, Randall Ten Haken3, Feng-Ming Spring Kong5.   

Abstract

PURPOSE: To investigate whether high-dose radiation to the pulmonary artery (PA) affects overall survival (OS) in patients with non-small cell lung cancer (NSCLC). METHODS AND MATERIALS: Patients with medically inoperable/unresectable NSCLC treated with definitive radiation therapy in prospective studies were eligible for this study. Pulmonary artery involvement was defined on the basis of pretreatment chest CT and positron emission tomography/CT fusion. Pulmonary artery was contoured according to the Radiation Therapy Oncology Group protocol 1106 atlas, and dose-volume histograms were generated.
RESULTS: A total of 100 patients with a minimum follow-up of 1 year for surviving patients were enrolled: 82.0% underwent concurrent chemoradiation therapy. Radiation dose ranged from 60 to 85.5 Gy in 30-37 fractions. Patients with PA invasion of grade ≤2, 3, 4, and 5 had 1-year OS and median survival of 67% and 25.4 months (95% confidence interval [CI] 15.7-35.1), 62% and 22.2 months (95% CI 5.8-38.6), 90% and 35.8 months (95% CI 28.4-43.2), and 50% and 7.0 months, respectively (P=.601). Two of the 4 patients with grade 5 PA invasion died suddenly from massive hemorrhage at 3 and 4.5 months after completion of radiation therapy. Maximum and mean doses to PA were not significantly associated with OS. The V45, V50, V55, and V60 of PA were correlated significantly with a worse OS (P<.05). Patients with V45 >70% or V60 >37% had significantly worse OS (13.3 vs 37.9 months, P<.001, and 13.8 vs 37.9 months, P=.04, respectively).
CONCLUSIONS: Grade 5 PA invasion and PA volume receiving more than 45-60 Gy may be associated with inferior OS in patients with advanced NSCLC treated with concurrent chemoradiation.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 24685448      PMCID: PMC4292798          DOI: 10.1016/j.ijrobp.2014.02.011

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  20 in total

1.  Prediction of radiation pneumonitis following high-dose thoracic radiation therapy by 3 Gy/fraction for non-small cell lung cancer: analysis of clinical and dosimetric factors.

Authors:  Dongryul Oh; Yong Chan Ahn; Hee Chul Park; Do Hoon Lim; Youngyih Han
Journal:  Jpn J Clin Oncol       Date:  2009-02-03       Impact factor: 3.019

2.  A Phase II study of synchronous three-dimensional conformal boost to the gross tumor volume for patients with unresectable Stage III non-small-cell lung cancer: results of Korean Radiation Oncology Group 0301 study.

Authors:  Kwan Ho Cho; Sung Ja Ahn; Hong Ryull Pyo; Kyu-Sik Kim; Young-Chul Kim; Sung Ho Moon; Ji-Youn Han; Heung Tae Kim; Woong Sub Koom; Jin Soo Lee
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-12-29       Impact factor: 7.038

3.  Stereotactic body radiation therapy (SBRT) for early-stage lung cancer.

Authors:  M Hiraoka; Y Matsuo; Y Nagata
Journal:  Cancer Radiother       Date:  2006-12-08       Impact factor: 1.018

4.  Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer: a dose-escalation phase I trial.

Authors:  Mark A Socinski; David E Morris; Jan S Halle; Dominic T Moore; Thomas A Hensing; Steven A Limentani; Robert Fraser; Maureen Tynan; Andrea Mears; M Patricia Rivera; Frank C Detterbeck; Julian G Rosenman
Journal:  J Clin Oncol       Date:  2004-11-01       Impact factor: 44.544

5.  High-dose radiation therapy for elderly patients with inoperable or unresectable non-small cell lung cancer.

Authors:  K Hayakawa; N Mitsuhashi; S Katano; Y Saito; Y Nakayama; H Sakurai; T Akimoto; M Hasegawa; M Yamakawa; H Niibe
Journal:  Lung Cancer       Date:  2001-04       Impact factor: 5.705

6.  Pulmonary resection after concurrent chemotherapy and high dose (60Gy) radiation for non-small cell lung cancer is safe and may provide increased survival.

Authors:  Robert James Cerfolio; Ayesha S Bryant; Virginia L Jones; Robert Michael Cerfolio
Journal:  Eur J Cardiothorac Surg       Date:  2009-02-23       Impact factor: 4.191

7.  High-dose radiotherapy or concurrent chemo-radiation in lung cancer patients only induces a temporary, reversible decline in QoL.

Authors:  Madelon Pijls-Johannesma; Ruud Houben; Liesbeth Boersma; Janneke Grutters; Katarina Seghers; Philippe Lambin; Rinus Wanders; Dirk De Ruysscher
Journal:  Radiother Oncol       Date:  2009-03-16       Impact factor: 6.280

8.  Prognosis of patients after pulmonary artery plasty for non-small cell lung cancer.

Authors:  T Obuchi; S Miyahara; T Higuchi; D Hamatake; T Imakiire; T Ueno; Y Yoshinaga; T Shiraishi; T Shirakusa; A Iwasaki
Journal:  Thorac Cardiovasc Surg       Date:  2009-12       Impact factor: 1.827

9.  High radiation dose may reduce the negative effect of large gross tumor volume in patients with medically inoperable early-stage non-small cell lung cancer.

Authors:  Lujun Zhao; Brady T West; James A Hayman; Susan Lyons; Kemp Cease; Feng-Ming Kong
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-03-23       Impact factor: 7.038

10.  Feasibility of high-dose three-dimensional radiation therapy in the treatment of localised non-small-cell lung cancer.

Authors:  A Bellière; N Girard; O Chapet; M Khodri; A Kubas; P-J Souquet; F Mornex
Journal:  Cancer Radiother       Date:  2009-06-13       Impact factor: 1.018

View more
  7 in total

1.  An individualized radiation dose escalation trial in non-small cell lung cancer based on FDG-PET imaging.

Authors:  Marie Wanet; Antoine Delor; François-Xavier Hanin; Benoît Ghaye; Aline Van Maanen; Vincent Remouchamps; Christian Clermont; Samuel Goossens; John Aldo Lee; Guillaume Janssens; Anne Bol; Xavier Geets
Journal:  Strahlenther Onkol       Date:  2017-07-21       Impact factor: 3.621

Review 2.  Specific toxicity after stereotactic body radiation therapy to the central chest : A comprehensive review.

Authors:  Feras Oskan; Gerd Becker; Martin Bleif
Journal:  Strahlenther Onkol       Date:  2016-11-03       Impact factor: 3.621

3.  Assessment of thoracic vasculature in patients with central bronchogenic carcinoma by unenhanced magnetic resonance angiography: comparison between 2D free-breathing TrueFISP, 2D breath-hold TrueFISP and 3D respiratory-triggered SPACE.

Authors:  Lili Wang; Peng Lv; Shuohui Yang; Mengsu Zeng; Jiang Lin
Journal:  J Thorac Dis       Date:  2017-06       Impact factor: 2.895

4.  Effect of Midtreatment PET/CT-Adapted Radiation Therapy With Concurrent Chemotherapy in Patients With Locally Advanced Non-Small-Cell Lung Cancer: A Phase 2 Clinical Trial.

Authors:  Feng-Ming Kong; Randall K Ten Haken; Matthew Schipper; Kirk A Frey; James Hayman; Milton Gross; Nithya Ramnath; Khaled A Hassan; Martha Matuszak; Timothy Ritter; Nan Bi; Weili Wang; Mark Orringer; Kemp B Cease; Theodore S Lawrence; Gregory P Kalemkerian
Journal:  JAMA Oncol       Date:  2017-10-01       Impact factor: 31.777

5.  Is pulmonary artery a dose-limiting organ at risk in non-small cell lung cancer patients treated with definitive radiotherapy?

Authors:  Jie-Tao Ma; Li Sun; Xin Sun; Zhi-Cheng Xiong; Yang Liu; Shu-Ling Zhang; Le-Tian Huang; Cheng-Bo Han
Journal:  Radiat Oncol       Date:  2017-02-01       Impact factor: 3.481

6.  Plasma levels of soluble programmed death ligand-1 may be associated with overall survival in nonsmall cell lung cancer patients receiving thoracic radiotherapy.

Authors:  Jing Zhao; Peng Zhang; Jianhua Wang; Qingsong Xi; Xueqi Zhao; Minghua Ji; Guangyuan Hu
Journal:  Medicine (Baltimore)       Date:  2017-02       Impact factor: 1.889

7.  Validation of an established deep learning auto-segmentation tool for cardiac substructures in 4D radiotherapy planning scans.

Authors:  Gerard M Walls; Valentina Giacometti; Aditya Apte; Maria Thor; Conor McCann; Gerard G Hanna; John O'Connor; Joseph O Deasy; Alan R Hounsell; Karl T Butterworth; Aidan J Cole; Suneil Jain; Conor K McGarry
Journal:  Phys Imaging Radiat Oncol       Date:  2022-07-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.